SEC Form 4 · accession 0001209191-18-027373
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Schiermeier
Officer — EVP, Corporate Strategy
Period of report
May 1, 2018
Accepted (ET)
May 2, 2018 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $20.56 | May 1, 2018 | A | 23,500 | A | — | Apr 30, 2028 | Common Stock | 23,500 | 23,500 | D |
Explanation of responses
- F1This option was granted on May 1, 2018 with respect to 23,500 shares of Common Stock, with 25% vesting on May 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.